An international study led by researchers at UCLA has found that a personalized vaccine targeting glioblastoma, the deadliest form of brain cancer, may help people live longer. Nearly 30 percent of people in the current trial have now survived for at least three years after receiving the vaccine.
Fred Hutchinson Cancer Research Center’s latest findings will be featured at the annual meeting of the American Society of Clinical Oncology, “Delivering Discoveries: Expanding the Reach of Precision Medicine,” to be held June 1–5 in Chicago. Here are several highlights:
Un fármaco utilizado en el cáncer sanguíneo puede resultar útil en el cáncer de mama triple negativo, descubrieron los investigadores de Mayo Clinic. El cáncer de mama triple negativo es uno de los tipos más agresivos y letales de cáncer de mama. El estudio se publicó en la Revista de Investigación Clínica.
Click here to go directly to the Cancer News Source
Bioengineers have developed micro-technologies that capture extracellular vesicles (EVs) released by brain tumors. The vesicles carry samples of the mutated genetic material and proteins causing malignancy that researchers can analyze to optimize precision cancer treatment.
On May 6, the National Institutes of Health will open national enrollment for the All of Us Research Program in collaboration the University of Pittsburgh and other partners.
明尼苏达州罗切斯特 – 5月6日美国国立卫生研究院将开放 “我们所有人”研究计划的全国注册。 根据国立卫生研究院的资讯，这项计划旨在推动具有各种不同背景的所有人的个人化预防，治疗和护理。
El 6 de mayo próximo, los Institutos Nacionales de Salud (NIH, por sus siglas en inglés) abrirán las inscripciones en todo el país para el programa de investigación “Todos nosotros”.
On May 6, the National Institutes of Health (NIH) will open national enrollment for the All of Us Research Program. According to the NIH the program is a momentous effort to advance individualized prevention, treatment and care for people of all backgrounds.
The All of Us Research Program officially opens for enrollment Sunday, May 6. Led by the National Institutes of Health (NIH), All of Us is an unprecedented effort to gather genetic, biological, environmental, health and lifestyle data from 1 million or more volunteer participants living in the United States. A major component of the federal Precision Medicine Initiative, the program’s ultimate goal is to accelerate research and improve health.
The majority of patients with diffuse large B cell lymphoma (DLBCL) can be treated effectively. However, people whose disease recurs face a shortage of good options, especially because the disease is driven by a complicated mix of genetic alterations. Genomic analysis by scientists at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard now offers a better framework for understanding the disease’s many forms, which will help to predict individual patient outcomes and guide personalized treatment.
Taking a biopsy of a brain tumor is a complicated and invasive surgical process, but a team of researchers at Washington University in St. Louis is developing a way that allows them to detect tumor biomarkers through a simple blood test.
Scientists have re-created brain neurons of obese patients using "disease in a dish" technology, offering a new method to study the brain's role in obesity and possibly help tailor treatments to specific individuals.
Ludwig Cancer Research released today the full scope of findings to be presented by Ludwig researchers at this year’s American Association for Cancer Research (AACR) Annual Meeting in Chicago, Ill., April 14-18, 2018. Research conducted by more than 100 Ludwig scientists will be presented in symposiums, plenaries, town meetings, education sessions and poster sessions.
A new type of cancer vaccine has yielded promising results in an initial clinical trial. The personalized vaccine is made from patients’ own immune cells, which are exposed to the contents of the patients’ tumor cells, and then injected into the patients to initiate a wider immune response. The trial, conducted in advanced ovarian cancer patients, was a pilot trial aimed primarily at determining safety and feasibility, but there were clear signs that it could be effective: About half of the vaccinated patients showed signs of anti-tumor T-cell responses, and those “responders” tended to live much longer without tumor progression than those who didn’t respond. The study is published today in Science Translational Medicine.
Researchers from The University of Texas MD Anderson Cancer Center have found a startling amount of new information about molecular features of tumors as well as identified previously unknown cancer subtypes based on a comprehensive analysis of 2,579 tumors from breast and four different types of gynecologic cancers. These new findings potentially could serve as a launching pad for future therapeutic studies.
The Princess Margaret Cancer Foundation announces the launch of Colour Your Hair to Conquer Cancer, a bold and engaging new fundraising initiative benefiting the Princess Margaret Cancer Centre.
The PhRMA Foundation will be partnering with the Personalized Medicine Coalition (PMC) to offer Value Assessment Challenge Awards in 2018, providing more than $80,000 to support scientific papers that advance solutions to a question: What are potentially transformative strategies and methods to define and measure value at all levels of decision making that are aligned with personalized/precision medicine?
Scientists have found a genetic trigger that may improve the brain’s ability to heal from a range of debilitating conditions, from strokes to concussions and spinal cord injuries.
Researchers from Queen’s University Belfast have demonstrated for the first time how molecular analysis of clinical trial biopsy samples can be used to help clinicians identify the key changes that occur in an individual patient’s bowel (colorectal) tumour prior to surgery, so clinicians can better understand and treat the disease.
New research from a UC Santa Cruz Genomics Institute-affiliated team from the Jack Baskin School of Engineering just published in the journal Nature Biotechnology attempts to close huge gaps in our genomic reference map. The research uses nanopore long-read sequencing to generate the first complete and accurate linear map of a human Y chromosome centromere. This milestone in human genetics and genomics signals that scientists are finally entering a technological phase when completing the human genome will be a reality.
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new Northwestern Medicine multi-site study.In the near future, patients won’t have to waste time and be disappointed with months of ineffective therapy, scientists said.
Personalized medicine is one step closer for consumers, thanks to tiny, implantable sensors that could give an early warning of a person’s developing health problems, indicate the most effective type of exercise for an individual athlete, or even help triage wounded soldiers. That’s the vision for a family of devices that scientists are now developing.
Joel Dudley, PhD, an internationally recognized investigator in translational bioinformatics and precision medicine, has been named Executive Vice President for Precision Health for the Mount Sinai Health System.
Today, in a late-breaking featured clinical research session at the American College of Cardiology Scientific Sessions 2018, researchers from Penn Medicine present first-of-its-kind data on the impact of real-time CYP2C19 genotype results when prescribing antiplatelet drugs in the clinic.
Research led by St. Jude Children’s Research Hospital offers the most comprehensive analysis yet of the genomic alterations leading to cancer in children and affirms the need for pediatric-specific precision therapies
For years, researchers have attempted to harness the full potential of gene therapy, a technique that inserts genes into a patient’s cells to treat cancer and other diseases. However, inserting engineered DNA molecules into cells is difficult. A team of engineers at Washington University in St. Louis has developed a new method that could make the process easier.
The world of DTC DNA test kits, namely for cardiovascular disease
Computer scientists from the University of Delaware and Georgetown University have developed a new system to rapidly determine which cancer drugs are likely to work best given genetic markers for a patent – the first publicly available system of its kind.
Gene editing has captivated scientists and medical providers with tantalizing visions of wiping out debilitating inherited diseases.
A clinical trial using genetic testing to match acute myeloid leukemia (AML) patients with new therapies is now open at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC). The center is one of seven cancer centers nationwide participating in the Beat AML® Master Trial, sponsored by the Leukemia & Lymphoma Society (LLS).
正在成为个体化医疗的重要组成部分。 微生物群落有助于改良诊断，及早发现和治疗疾病，并降低疾病风险。 Mayo Clinic的研究人员在最新一期的医学杂志Mayo Clinic Proceedings上发表了一篇综述来介绍其重要性。
ROCHESTER, Minn. – In the latest issue of Mayo Clinic Proceedings, Mayo Clinic researchers reviewed the importance of the microbiome as a key component of personalized medicine to improve diagnosis, reduce disease risk and optimize early detection and treatment. The microbiome is the combined genetic material of the microorganisms in a particular environment.
Integrative medicine? That’s stuff like acupuncture, yoga and meditation, right? Yes, they can be part of it, but for many practitioners integrative medicine is about prevention and wellness as well as treatment and incorporates more conventional approaches than alternative or complementary therapies.
A simple blood test is allowing Vanderbilt University Medical Center (VUMC) researchers to determine which patients should be prescribed varenicline (Chantix) to stop smoking and which patients could do just as well, and avoid side effects, by using a nicotine patch.
UNC researchers use cognitive computing to scour large volumes of data from scientific studies and databases to find potentially relevant clinical trials or therapeutic options for cancer patients based on the genetics of their tumors.
Work underway in a laboratory at the University of Delaware suggest certain drugs can prevent and reduce changes to the brain caused by mistreatment at an early age.
By studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC’s Jonathan Schisler, PhD, have identified a possible genetic basis for coronary artery disease (CAD), as well as potential new opportunities to prevent it.
Ann & Robert H. Lurie Children’s Hospital of Chicago is one of the few centers participating in ASPIRO, an international Phase 1/2 clinical trial of a gene therapy product called AT132 for X-linked myotubular myopathy – a rare disease characterized by severe muscle weakness, breathing difficulty and early death.
Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.
Rural counties continue to rank lowest among counties across the U.S., in terms of health outcomes. A group of national organizations including the Robert Wood Johnson Foundation and the National 4-H Council are leading the way to close the rural health gap.
CU Cancer Center study examines current RECIST guidelines in an effort to bring them up to speed with new complexities presented by the latest targeted therapies.
Sbarro Health Research Organization President Antonio Giordano introduces program at National Italian American Foundation 42nd Anniversary Gala Weekend In Washington D.C.
Leading experts in the field of sickle cell disease (SCD) research will convene in Washington, D.C., for the Physiological and Pathophysiological Consequences of Sickle Cell Disease conference (November 6–8). The conference, organized by the American Physiological Society (APS), will explore SCD—the world’s most prevalent single-gene mutation disease—and new research on preventing and reversing its deadly consequences.
For some cancer patients, the road to remission and healing can have its share of speed bumps. That’s particularly true of patients with non-small cell lung cancer (NSCLC) who develop a secondary, or acquired, resistance to immunotherapy, which initially was effective against their tumors.
A new type of DNA editing enzyme, developed in HHMI Investigator David Liu’s lab, lets scientists directly and permanently change single base pairs of DNA from A•T to G•C. The process could one day enable precise DNA surgery to correct mutations that cause human diseases.
Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse. The findings provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell receptors, or TCRs.
An international team of scientists, led by structural biologists at Van Andel Research Institute, has shed new light on a critical step in DNA replication, offering fresh insights into a fundamental process of life and driver of many different diseases, including cancer.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right